Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Kevin H. Douglas

Member

Nashville
(615) 742-7767 TEL
(615) 742-0454 FAX

Kevin H. Douglas

Member

Nashville
(615) 742-7767 TEL
(615) 742-0454 FAX
Nashville
(615) 742-7767 TEL
(615) 742-0454 FAX

Kevin Douglas is the Chair of the firm's Corporate & Securities Practice Group. He has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin's public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative experience has ranged from providing SEC disclosure advice to the audit committee of a Fortune 100 company to representing an NYSE-listed company in connection with its $4.3 billion acquisition by another public company to representing another NYSE-listed company in connection with its issuance of $2.2 billion in senior notes. Kevin has also represented private companies in a wide variety of mergers and acquisition matters.

Kevin Douglas is the Chair of the firm's Corporate & Securities Practice Group. He has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin's public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative experience has ranged from providing SEC disclosure advice to the audit committee of a Fortune 100 company to representing an NYSE-listed company in connection with its $4.3 billion acquisition by another public company to representing another NYSE-listed company in connection with its issuance of $2.2 billion in senior notes. Kevin has also represented private companies in a wide variety of mergers and acquisition matters.

Kevin represents public companies, private equity-backed companies and other private companies. His broad corporate practice involves:

  • Mergers & Acquisitions – Representing public and private companies in connection with mergers and acquisitions.
  • Corporate Finance – Advising clients in connection with public offerings, Rule 144A offerings, private placements and venture capital investments.
  • Securities Laws Compliance – Advising public company clients in connection with the preparation of Form 10-Ks, 10-Qs, 8-Ks, proxy statements and earnings releases.
  • Corporate Governance – Providing clients with advice related to compliance with the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act and other federal securities laws requirements; compliance with stock exchange corporate governance listing standards, committee charters and corporate governance guidelines, board and committee composition issues, internal control and disclosure control matters, Regulation FD, insider trading policies and 10b5-1 trading plans.
  • Shareholder Activism – Assisting with shareholder rights plans, proxy access bylaws, contested director elections, classified boards, advance notice bylaws, Rule 14a-8 shareholder proposals, ISS and other proxy advisory firm-related matters, and Section 13 of the Securities Exchange Act and standstill agreements.
  • Executive Compensation – Advising on executive compensation disclosure requirements applicable to public companies and related topics.

Kevin is the co-editor of the firm's Securities Law Exchange blog, where he provides commentary on a variety of corporate and securities law issues.

Prior to joining the firm, Kevin practiced at Latham & Watkins in Washington, D.C. and Sherrard & Roe, PLC in Nashville.

+ Read More

- Read Less

Featured Experience

View Experience

Memberships

American Bar Association

American Health Lawyers Association (AHLA)

News

View More

Representative Experience

View More

Publications

View More

Past Events

View More

Media Mentions

View More

Accolades

Best Lawyers in America® — Corporate Law (2013-2018)

Vanderbilt Law Review — Member (1996-1998)

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.